# Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

> **NCT00688558** · PHASE2 · COMPLETED · sponsor: **Akros Pharma Inc.** · enrollment: 92 (actual)

## Conditions studied

- Dyslipidemia

## Interventions

- **DRUG:** JTT-705 600 mg and simvastatin 40 mg
- **DRUG:** Placebo and simvastatin 40 mg

## Key facts

- **NCT ID:** NCT00688558
- **Lead sponsor:** Akros Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2004-12
- **Final completion:** 2006-03
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2008-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00688558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00688558, "Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00688558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*